ENTA Enanta Pharmaceuticals Inc.

61.77
-1.74  -3%
Previous Close 63.51
Open 63.35
Price To Book 2.71
Market Cap 1,215,732,988
Shares 19,681,609
Volume 85,705
Short Ratio
Av. Daily Volume 203,886
Stock charts supplied by TradingView

NewsSee all news

  1. Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that three preclinical posters on EDP-305,

  2. Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to

  3. Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly,

  4. New Data from Enanta's Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new data from

  5. AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

    NORTH CHICAGO, Ill., Sept. 26, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b trial to commence by end of 2019.
EDP-938
Respiratory Syncytial Virus
Phase 2 data met primary endpoint - September 25, 2019. Pruritus was present in approximately 51% of the subjects in the 2.5mg arm. Phase 2b trial to be initiated 1H 2020.
EDP-305 ARGON-1
Non-alcoholic steatohepatitis (NASH)
Phase 2 enrollment to continue through 2019.
EDP-305 INTREPID
Primary biliary cholangitis (PBC)
Approval announced August 3, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
Phase 2b ongoing. Data released November 2015. Phase 3 initiated
ABT-493
HCV
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved July 25, 2017.
VIEKIRA PAK - once-daily, fixed-dose formulation through Abbvie
HCV - genotype
Phase 1 trial initiation announced July 8, 2019.
EDP-514
Hepatitis B virus (HBV)

Latest News

  1. Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that three preclinical posters on EDP-305,

  2. Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to

  3. Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly,

  4. New Data from Enanta's Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new data from

  5. AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

    NORTH CHICAGO, Ill., Sept. 26, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval

  6. Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH

    Primary endpoint, ALT reduction at week 12, was met in the 2.5mg dosing group Key secondary endpoint, reduction in liver fat content as measured by MRI-PDFF at week 12, was met in the 2.5mg dosing

  7. New Data from Enanta's Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019

    Late-breaker oral presentation of EDP-938 on October 3 at 2:35 pm ET   Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs